

Index

24-hour noninvasive automatic ambulatory blood pressure 130

A

a priori 47, 48, 148, 225, 237, 266, 270, 271, 281, 285, 314, 340, 344
absolute difference 310
abstract 322, 323
academic advising 339, 341
academic detailing 228
active control 30, 32, 45, 48, 50, 65–67, 69, 75, 76, 108, 119, 136, 140
ADOPT (a diabetes outcome prevention trial) 54
adoption studies 195
adverse drug events (ADEs) 44, 47, 75, 81, 83, 90, 98, 107–109, 149, 208, 212
advisee 340, 341
advising 339–344
Agency for Healthcare Research and Quality (AHRQ) 105, 243
allele 186, 188–191, 195–197, 199, 200, 202
allelic heterogeneity 199, 202
ALLHAT study 59, 60, 334
allocation ratio 33
allotted time 349
alpha level 158
alpha-tocopherol, beta carotene cancer prevention study 42, 59
alternative hypothesis 16, 19–21, 490, 69, 201, 271–273, 276, 277, 288, 313, 315
Amberson, J.B. 6
analysis of variance (ANOVA) 283, 285, 319
analytic studies 21, 210
ancestry informative markers (AIMS) 201

angina 54, 58, 59, 88, 116, 117, 124–127, 130, 133, 135, 136, 139, 259
Antihypertensive Safety and Efficacy and Physician and Patient Satisfaction in Clinical Practice: Results from a Phase IV Practice-based Clinical Experience Trial with Diltiazem LA 80
anturane reinfarction trial 44
Anzio effect 122
Apologizing 348
APPROVe trial (Adenomatous Polyps Prevention on Vioxx) 83
area under the curve (AUC) 255, 256
as treated analysis 45
assay sensitivity 67, 68
association 15, 16, 21, 22, 24–26, 34, 35, 73, 83–85, 88, 90, 96, 132358, 133, 135, 172–174, 185, 188–190, 194–202, 205, 206, 208–211, 214, 216, 232, 283–298, 299, 300, 302–305, 310, 312, 314, 316, 317, 334
association studies 185, 188–190, 194–199, 202
attributable fraction 197
attributable risk (AR) 197, 287, 289, 292
attrition rates 149, 150, 240
audience recall 346
audience-centered stage 348
audiovisuals 349, 351
AV equipment 349
azathioprine 214

B

background 9, 76, 118, 157, 200, 241, 266, 322, 324, 325, 328, 329
barrier analysis 234
basepair 186, 187
Bayes, Thomas 250

- Bayes' Formula 253, see also Bayes' Theorem
- Bayes' Theorem 250, 253 see also Bayes' Formula
- Bayesian approach 159, 281, 308, 317, 318
- Bayesian logic 250
- beta-blocker heart attack trial 132
- bias 6, 10, 23, 24, 34, 35, 60, 68, 72, 76, 78, 106, 107, 136, 147, 163–168, 170, 172, 175, 177, 189, 201, 211–217, 232, 234–238, 295–298, 299–303, 318, 334
- binary trait 193
- black-box' warning 87, 89, 99
- blindness 6, 189
- body of the talk 346
- Bonferroni adjustment 158
- Bradford Hill criteria 296
- Bradford Hills tenets of causation 295
- budget 98, 147, 266, 274, 276, 322, 324, 328
- bullet points 348, 349
- C**
- calcium channel blocker (CCB) controversies 334
- Canadian Implantable Defibrillator Study (CIDS) 58
- candidate gene 188, 197, 198, 201
- cardiac arrhythmia suppression trial (CAST) 54, 131, 132
- career development plan 340, 344
- career development programs 342
- career goals 341, 344
- career planning 341
- carotid artery disease 335
- carotid artery endarterectomy 105
- case cohort design 25, 207, 214
- case reports 21, 22, 77, 88, 90, 104, 105, 131, 208, 209
- case series 21, 22, 103, 208, 209
- case-crossover design 71, 72, 214–216
- case-referent studies 211
- case-time control design 214, 216
- categorical analyses 283
- categorical data 283, 318
- causal chain 305
- causal pathway 304
- causation 15, 30, 73, 293–296, 304
- cause-and-effect inference 4, 232, 238, 303
- Center for Drug Evaluation and Research (CDER) 99, 110
- Centers for Medicare and Medicaid Services (CMMS) 105, 231
- cerivastatin 88, 205
- chance effect 299
- chelation therapy 127
- chi-square distribution 285, 286
- chi-square statistic 285–287
- chromosomes 186–191, 198
- cimetidine 209
- cisapride 88, 205
- class I recalls 82
- classical conditioning 123
- clinical microsystem 225, 229, 230, 244
- clinical pharmacology 80, 89, 101, 205
- clinical trial 4–6, 8, 10, 14, 21, 29–60, 66, 67, 76, 77, 79, 81–85, 87, 90, 99, 102, 103, 105, 108, 109, 115–117, 120, 128, 132, 134–139, 147–149, 155, 160–164, 167, 170, 175, 179, 205, 207, 208, 224, 225, 232–234, 238, 240, 243, 258, 288, 291, 295, 317, 335
- clinical trial of reviparin and metabolic modulation of acute myocardial infarction (CREATE) 81
- clone 191
- cluster RCT 232–234, 237, 238, 243
- cluster-adjusted sample size 239
- cluster-based randomization 236
- Cochran's Q test 171
- Cochrane collaboration 178
- coding regions 187, 188, 196, 202
- Cohen's kappa 251
- cohort study 10, 21–26, 207, 208, 21–214, 287, 291, 300, 304, 307
- collaborative model 226
- communicating 335, 337, 346
- community health advisor (CHA) model 226
- community-based implementation tools 226
- comparator group 21, 30, 65
- comparison group 31, 38, 41, 42, 45, 200, 209, 210, 214, 232, 235, 237–239, 241, 242, 276, 323
- compliance 31, 38, 39, 44, 46, 67, 80, 125, 126, 132, 133, 136–139
- compliers only analysis 43–45, 238
- composite endpoint 4, 31, 55–57
- computer-based systems 230
- computerized provider order entry (CPOE) 230
- conclusion 10, 13, 17, 32, 49, 56, 57, 59, 60, 68, 69, 103, 104, 108, 116, 132, 136, 138, 149, 150, 158, 164, 168, 177, 199, 234, 280, 295, 297, 303, 305, 313, 315, 326, 336, 346, 347, 351
- conditional probabilities 216, 253, 284, 285
- conditioned answers 115

confidence intervals 72, 168, 173, 174, 275, 273, 288, 309, 310
 confounder 30, 34–36, 44, 173, 197, 202, 214, 216, 232, 279, 296, 299, 303–305, 314, 316, 317
 confounding 10, 30, 35, 72, 78, 134, 200, 202, 209, 211, 212, 216, 232, 235, 276, 295, 297, 298, 299–305, 317, 333
 congestive heart failure (CHF) 54, 127–130, 136, 137, 139, 230, 257
 CONSORT 26, 233, 238, 243
 constancy assumption 67, 68
 contextual learning 235
 continuing medical education (CME) 178, 227, 228, 235, 237, 238, 242
 Continuous Quality Improvement (CQI) 229
 contract 50, 54, 322, 328
 control groups 6, 22, 23, 30, 32, 34, 35, 41, 42, 44, 51, 55, 65, 103, 116, 117, 120, 121, 129, 136, 138–140, 171, 172, 189, 213, 214, 271, 276, 277, 288, 291, 316, 317, 327, 335
 Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints study (CONVINCE) 50
 conversational 348, 351
 cooperation rate 146
 cooperative agreement 328
 copy number variants (CNV) 189, 202
 co-relationship 293
 Coronary Drug Project 44, 101, 134
 Coronary Drug Project Research Group 132
 correlate 54, 128, 196, 303
 cosegregation 196
 counterfactual outcome 295
 covariate 214, 216, 217, 293, 294, 298
 covarying 317
 cross classifications 283–285
 cross sectional study 21, 22, 26, 208–210
 crossover design 69–72, 76, 214–216
 cut-point 14, 35, 254
 cyclophosphamide 214

D

data dredging 46, 313
 data function 318
 data safety and monitoring boards (DSMBs) 32, 155–161
 data types 318
 Declaration of Helsinki 6, 31, 98, 135, 137, 138, 140
 deductive reasoning 297
 definition of clinical research 3–10, 29

Department of Health, Education, and Welfare (HEW) 97
 Dependence 166, 284, 285, 287
 descriptive studies 21
 DESI Review 8
 detectable effect 265, 273, 274
 deterministic variable 293
 development phase 101, 333, 334
 diagnostic testing 249–251
 dichotomous 192, 283, 318, 319
 differential misclassification 303
 disparities research 222
 dispersion of outcomes 309
 Division of Drug Marketing and Communications (DDMAC) 110
 DNA 186, 187, 189, 191–193, 195, 201
 dose ranging studies 75, 76, 102
 dose-comparison control 119, 135
 double blind 6, 29, 30, 40–42, 45, 50, 65, 75, 79, 82, 83, 117, 123, 124, 127, 130, 132, 134, 137
 double-blind trial 40, 41, 75, 79, 82, 179
 Drug Efficacy Study Implementation (DESI) 8, 98
 drug utilization studies 77, 84, 209, 210
 DSMB, see data safety and monitoring boards
 data and safety monitoring plan (DSMP) 32, 156

E

early study termination 156
 echocardiography 128, 129
 ecologic fallacy 209
 ecologic studies 10, 21, 208, 209
 econometric 217
 effect modification 298, 299, 305
 effect-cause 295, 296
 effectiveness 31, 37–39, 43, 50, 77, 78, 81, 84, 86, 88, 90, 98, 101, 103, 105, 127, 136, 138, 140, 167, 180, 207, 226–228, 230, 231, 241, 290
 efficacy 7, 8, 31, 34, 37, 38, 46–48, 52, 59, 66, 75–77, 79, 80, 84, 86, 87, 89, 90, 98, 100–106, 108, 109, 115, 117, 119, 127–129, 131, 132, 134–136, 138, 139, 155, 157, 158, 164, 167, 175, 205, 333
 electronic pharmacy databases 211
 eligibility 5, 31, 33, 36, 44, 45, 146, 147, 166, 323, 342
 eligibility fraction 146, 147
 embargo rule 336
 EMBASE 166
 empirical observations 297

English language bias 168
 enrollment fraction 146, 147
 enrollment process 147
 enumeration statistic 286
 environmental factors 185, 195, 197–200,
 202, 224
 equality of groups 271
 equipoise 32, 40, 107
 equivalence 50, 65–69, 78, 81, 136, 159, 271
 equivalence margin 66
 equivalence of groups 271
 equivalence testing 30, 31, 48–50, 65,
 67, 69, 77, 81
 error rates 201, 272–276, 281
 errors of commission 222, 223, 271, 272
 errors of omission 222, 223, 271
 estimation 164, 168, 197, 238, 301,
 307–311, 319
 ethics 4, 15, 16, 29, 31, 42, 54, 115, 134, 135,
 145, 147, 192
 etiologic fraction 197
 European Medicines Agency (EMA) 102
 evidence based medicine 3, 164, 178, 179
 evidence-based content 235
 exclusion criteria 75, 171, 327
 exercise tolerance 124–126, 128, 129, 139
 expectations 19, 117, 130, 139, 146, 156, 191,
 202, 235, 339–341, 348
 expected 25, 39, 48, 52, 55, 66, 76, 89, 107,
 120, 131, 152, 157, 158, 174, 189, 199,
 201, 206, 208, 209, 216, 251, 271, 274,
 279, 285–287, 289, 293, 294, 326, 328,
 336, 340
 exploratory data analysis 313
 exposure 9, 10, 14–16, 21–26, 35, 65, 71, 72,
 78, 90, 129, 136, 138, 160, 171, 192,
 196–198, 202, 206, 207, 209–217, 235,
 238, 289, 294–298, 299–305, 310,
 316–318, 323, 347
 exposure effect period 72
 external advisory committee 344
 external validity 10, 240, 328
 externally controlled trials (before-after
 trials) 65, 72

F

factorial design 42, 70, 71
 factual outcome 295
 false discovery rate (FDR) 201
 familial aggregation 193, 194
 FDA Amendments Act of 2007 80, 100
 FDA historical considerations 95
 fear centered stage 348

feasibility studies 102
 feasible 200, 232, 236, 324, 327
 feasible study plan 323
 file-drawer problem 167
 Fisher 6, 17
 fixed effects 173
 Fleiss' kappa 251
 Food and Drug Administration Modernization
 Act of 1997 111
 Food, Drug and Cosmetics Act 7, 96–98,
 110, 119, 134
 forest plot 174, 175
 founder population 200
 fringe benefits 342
 'fugitive' reports 166
 funnel plot 168
 futility studies 102, 103

G

Galen 4, 5, 116
 gene glass 164, 170
 gene variants 185, 199
 gene-environment interaction 198
 generalizability 33, 36–39, 84, 104, 145, 146,
 177, 234, 240
 generalized estimation equations 238, 319
 genesis phase 333
 genetic epidemiology 185, 186, 189, 193,
 194, 198, 202, 203
 genetic marker 10, 187, 189, 196, 197
 genome 185–189, 191, 193, 194, 197–202
 genome wide association studies (GWAS) 198
 genomic control 200
 genotype misclassification 201
 genotypes 188, 189, 191, 197, 198, 200, 201
 good clinical practice (GCP) 6, 98
 good medical practice (GMP) 98
 goodness of fit 286
 Gossett, William Sealy 17
 Grabbers 346, 347, 351
 Greenberg Report 155
 group-time interaction variable 238

H

haplotype 188, 190, 191, 196, 197, 200, 201
 HapMap project 198
 Hardy-Weinberg equilibrium 189, 201, 202
 Hawthorne effect 42
 Haybittle-Peto method 158
 hazard period 72
 headline potential 335
 head-to-head comparison 207

Health Insurance Portability and Accountability Act (HIPAA) 145, 151, 234

Heckler 350

Hereditary 185, 186

Heterozygotes 188, 189

hierarchical data structure 239

historic paradigm 178

historical control 72, 73, 135, 136

history of clinical research 4, 6

Holter monitors 131, 139

hybrid designs 213, 216

hydrochlorothiazide 335

hypertensive patients 50, 335

hypothesis 5, 9, 15–17, 19–21, 45–51, 54, 58, 67–69, 102, 103, 120, 164–167, 173, 174, 195, 198, 201, 207, 232, 237, 239, 250, 266, 270–281, 285, 286, 288, 293, 297, 302, 307, 308, 312–315, 323–325

hypothesis generating 47, 165, 166, 198, 207

hypothesis testing 17, 20, 49, 66, 68, 166, 274, 278, 281, 285, 288, 307, 308, 312, 313, 315

I

I2 171

iatrogenic adverse event 222

ICH Mission Statement 100

ILLUMINATE trial 160

immortal time bias 213

implementation randomized trial 233, 236–240

Implementation research 77, 221–245

incident rates 289

Inclusion criteria 33

independent review 319, 328, 344

index time 215

individual patient data (IPD) 125, 131, 163, 165

inductive inferences 19, 297

inductive logic 17, 19, 20, 297

inductive reasoning 297

industrial-style quality improvement 225, 229

inference 4, 13, 17, 19, 31, 51, 60, 186, 191, 199, 232, 238, 266, 267, 269, 271–273, 280, 281, 286, 294–297, 303, 308

inferential understanding 307

inflation factor (IF) 239

influence analysis 172

information bias 211, 297

information fraction 157, 159

information technology (IT) 230, 244

Ingelfinger rule 336

innovation diffusion 224

innovation uptake 224

insertion/deletion 187, 189

Institute of Medicine 8, 89, 99, 100, 222, 240

instrumental variable analysis 216, 217

intention to treat analysis 4, 30, 39, 43, 109, 115, 133

inter and intra-variability of test interpretation 250

interim analyses 155–159

interim safety reports 158

intermediate endpoint 51, 54

internal mammary artery ligation 127

internal validity 10, 38, 84, 238, 299, 303

International Committee of Medical Journal Editors (ICMJE) 234

International Conference on Harmonization (ICH) 67, 100

internet-based strategy 235

interviewer bias 302

intraarterial monitoring 130

intrafamily correlation coefficient (ICC) 194, 239

investigational new drug (IND) application 101

investigator bias 167, 170

itrofurantoin 209

J

Jadad, and Newcastle-Ottawa 174

joint, marginal, and conditional probability 284, 285

K

K awards 342

K01/K08 research/clinical scientist 328

K23 and K24 patient oriented research 328

K23 grants 8, 342, 344

K24 grants 8, 328, 342, 344

K30 3, 8, 344

kappa statistic (k) 250–252

Kefauver hearings 98

1962 Kefauver-Harris drug amendments 98, 103

Kelsey, Francis 7

know-it-all 350

Koch's postulates 295

L

Lanarkshire milk experiment 35

Lan-Demets modification 158

large simple trial (LST) 65, 73, 7, 78,
81, 82, 177
least squares regression line 292
left ventricular (LV) function 128
likelihood 17, 30, 32, 70, 73, 82, 168, 191,
193, 196, 197, 217, 234, 239, 249–251,
253, 258, 260, 294, 310, 311
Lind, James 5, 6
linkage 77, 188–190, 194–196, 198, 234
linkage disequilibrium (LD) 189
lipid research clinics coronary primary
prevention trial 120, 132
location bias 168
locus 186–190, 196, 198–200
lod score 196
logistic regression model 133, 278
losses to follow-up 31, 40, 50, 145
lung volume reduction surgery (LVRS) 104,
105

M

Mantel-Haenszel-Peto method 174, 304
manual of operations (MOOP) 156
masking 3, 29, 31, 38, 40, 41, 70
Massengill Company 96
Master of Science Degree in Clinical
Research 344
Matching 6, 23, 30, 34, 72, 216, 236, 237,
299, 304, 317
maturation phase 333, 334
measurable trait 192
measure of association 172–174, 287, 289,
291, 300, 302, 303, 310
measure of precision 168
media 31, 60, 301, 302, 333–337, 350, 351
Medical Research Council 6, 129
MEDLINE 166, 167
'MedWatch' 83, 208
Mendel's first law 186
mentee 339–341, 344
mentor 329, 339–344
mentor's responsibilities 341
mentored NIH career development
awards 328
mentored research scientist development
award (K01) 328
mentoring 339–344
mentorship 339, 340
meta-analyses weaknesses 339, 340
meta-analysis 4, 41, 52, 82, 84, 130,
163–180, 234, 334
methodological flaws 334
methodological issues 115, 202

methotrexate 214
migration studies 195
MILIS study 45
minimum detectable difference 274, 279
minority recruitment 145, 150
misclassification bias 303
missense 187
monotherapy 206
MRFIT 41, 42, 59
multicenter isradipine diuretic atherosclerosis
study (MIDAS) 335
multi-factorial disorders 185
multilevel programs 234
multimodal strategies 235
multiple "peeks" 314, 316
multiple comparisons 158, 202, 232, 281
multivariable model 173, 216, 238
multivariate analysis 298, 305, 317, 319
mutation 187–190, 195
myocardial ischemia reduction with aggressive
cholesterol lowering (MIRACL) 58, 59

N

N of 1 trial 65, 70
naltrexone 123, 124
narrative reviews 164
national diet-heart study 120
national emphysema treatment trial 105
National Health Service 146
National Institutes of Health Revitalization
Act 150
natural history 70, 323
natural history of the disease 15, 52, 72,
115, 117, 131, 136, 199, 206
nature of the disease 206
necessary and sufficient 295
needs assessment 235
nested case control 23, 24, 208, 214
new drug applications (NDA) 79, 85,
99, 104, 124, 131
NIH policies 327
nitrate tolerance 126
no treatment control 30
nocebo 115–140
nominal 192, 235, 314
nomogram 259–261
non-differential misclassification 302, 303
noninferiority 49, 66–68
noninferiority margin 50, 66, 69
noninferiority testing 50, 66, 68, 69, 81
non-mentored senior awards 342, 344
nonparametric analysis 196
non-parametric test 285, 286

- non-sense 187
- nonsteroidal antiinflammatory drugs (NSAID) 205, 211
- normal distribution 286
- novice speakers 348
- null hypothesis 17, 19–21, 45, 49–51, 67–69, 102, 103, 173, 201, 271–273, 275, 276, 279, 286, 288, 297, 312–315, 323
- number needed to treat (or harm), NNT (or NNH) 174, 175, 265, 283, 291–293
- Nuremberg Code 6, 31, 135, 137, 138

- O**
- O'Brien-Fleming method 158
- observation bias 300, 302
- observational study, a monitoring board (OSMB) 156, 160, 161
- observed 34, 41, 42, 60, 116, 118–121, 128, 130–132, 165, 166, 171, 174, 187, 189, 191, 195, 199, 209, 212, 216, 232, 238, 239, 251, 252, 268, 271, 285–287, 294, 296, 298–300, 303, 304, 312, 313, 315, 317
- odds ratio 172–174, 176, 177, 198, 207, 210, 258, 270, 275, 278, 279, 283, 289–292, 299, 301, 302, 311, 312
- opinion leader strategies 228
- opt in approach 146, 147
- opt out approach 146, 147
- oral lecture 346
- oral presentation 346
- ordinal data 318
- organization-based implementation tools 229
- outcome 6, 8, 14, 15, 18, 22–26, 30–32, 34–36, 39, 41, 44, 46, 48, 51–54, 56–59, 71–73, 77, 81, 82, 84–86, 90, 103, 106, 107, 109, 118, 127, 132–134, 136, 137, 139, 151, 156, 158, 159, 165, 168, 170–174, 192, 193, 195, 199, 202, 206, 207, 209–217, 223, 225–227, 229, 230, 232, 234–240, 242, 250, 269–271, 273, 274, 276, 278, 283, 288–291, 294–297, 299, 300, 302–305, 309, 310, 312, 314, 316–318, 323, 326, 335, 336, 341
- overviews 4, 21, 163, 221, 226, 232, 326

- P**
- p value 14, 17, 45, 158, 176, 201, 265, 266, 268, 275, 283, 297, 299, 308, 312–316
- paired measures 318
- parachute intervention 179
- paradox of Theseus 170
- parallel group 65
- parallel group design 6, 30
- parameter value 268, 315
- parameters 6, 19, 85, 107, 121, 134, 267, 268, 273, 275, 278, 279, 292, 293, 301, 308–312, 315, 317
- parametric linkage 196
- PASS software package 275
- patient enrollment 327
- patient oriented research 4, 328, 342–344
- patient-based implementation tools 226
- pay-for-performance (P4P) 231
- Pearson product-moment correlation coefficient 294
- pedigree analysis 191
- peer review process 321
- per protocol analysis 43, 68, 238
- Pettiti's steps 166
- pharmaceutical research and manufacturers of America (PhRMA) 110
- pharmacodynamics 75, 76
- pharmacoeconomic studies 78, 84, 85
- pharmacoepidemiology (PE) 205–207
- pharmacogenetics 82, 199
- pharmacokinetics 75, 76, 89, 102
- pharmacovigilance 75, 77, 78, 82, 83, 89, 90, 217
- phase I trial 155
- phase III trial 75–79, 86, 87, 155
- phase I-III trial 75, 76
- phase IV studies 75, 78–80, 87, 89
- phenotype 185, 191–198, 200, 202
- phenotype variation 191
- phocomelia 208
- physician audit and feedback 228
- physician experience studies (PES) 80, 87
- physician's health study 70, 132, 134
- pilot data 326
- placebo 3–6, 8, 16, 30–33, 38–42, 44, 45, 47–49, 54, 59, 65–70, 72, 75, 76, 104, 106–109, 115–140, 149, 160, 163, 171, 172, 176, 235, 288
- placebo control 3, 30, 31, 41, 42, 48, 54, 65, 66, 116, 117, 119, 120, 124, 125, 127–131, 134–140
- placebo effect 70, 107, 115–141
- placebo orthodoxy 139, 140
- placebo paradox 119
- Pocock method 158
- podium 346
- pointer 349
- polio 6, 8

- polymorphism 185, 187–189, 196, 197
 pooled analyses 163, 350
 Popper, Karl 179, 297
 Popperian view 297
 population characteristics 85, 327
 positive and negative likelihood ratios
 (PLR and NLR) 258–260
 postdoctoral fellowship 328
 postmarketing commitments (PMC's) 78–80
 postmarketing research 75–92, 207
 postmarketing surveillance 75, 89, 209
 post-test probability 252–255, 259, 308
 power 10, 33, 36, 39, 46, 48, 50, 51, 55, 86,
 87, 100, 116, 129, 149, 163, 164, 173,
 191, 197, 198, 201, 237–239, 265–281,
 314–316, 340
 power analysis 265–267, 269, 275, 276, 278,
 280, 281
 PowerPoint 349
 predictive value 249, 250, 253, 260
 predictor variables 314
 preliminary studies 322, 325, 327–329
 preliminary studies section 325, 326
 premarketing studies 75–77
 prescription drug user fee act (PDUFA) 99,
 100, 111
 presentation skills 345–351
 pretest odds 258
 pre-test probability 251
 prevalence of disease 200, 254
 privatization of clinical research 147
 proarrhythmia 125, 131
 probabilistic reasoning 250
 probability 18–20, 46, 76, 190, 216,
 250–255, 258, 259, 261, 272, 273,
 275, 278, 283–285, 287–290, 297,
 301, 303, 308, 315, 324
 PROBE design 41, 73, 77, 82
 procedural advising 341
 “proof of concept” studies 55, 102
 propensity score risk adjustment 216
 proportions, rate, risk and prevalence 208
 prospective case control 289
 prospective, randomized, open-label, blinded
 endpoint (PROBE) design, see PROBE
 design
 protected health information (PHI) 151
 protected time 341, 342, 344
 protégé 339
 protein truncation 187
 provider-based implementation tools 227
 public speaking 345
 publication bias 163, 165, 167, 168,
 170, 175, 177, 234
 PUBMED 115, 166
 pulmonary artery balloon-floatation
 catheterization 128
- Q**
 quantitative 56, 163, 164, 168, 172, 192–194,
 198, 206, 250, 265, 267
 quantitative analyses 163
 quantitative reviews 163
 question and answer period 350
- R**
 R01 323
 radionuclide ventriculography 128
 random effects 173, 238
 random sample 25, 120, 148, 173, 215, 286,
 287, 301
 random variation/chance 299
 randomization 3, 6, 7, 29–35, 38, 39, 41–47,
 59, 65, 69, 120, 133, 149, 232, 233,
 236–239, 241, 300, 304, 316, 317
 randomization: simple, blocked, stratified 33
 randomized controlled trial 14, 16, 21, 24, 25,
 29, 30, 32, 35–37, 42, 49, 50, 57, 60,
 65, 66, 68, 70–73, 75, 78, 80, 81, 84,
 90, 103, 104, 106, 107, 109, 121, 160,
 167, 174, 177, 178, 179, 208, 214,
 221–244, 291, 296
 rapport 152, 346, 347
 RCT, see randomized controlled trial
 real world 38, 40, 41, 48, 80, 82, 84, 86,
 173, 233, 242, 269, 271
 reasoning 250, 297
 recall bias 23, 24, 72, 78, 211, 214, 302
 receiver operator characteristic curves
 (ROC) 249, 253–257
 recombination 190, 196
 recruitment 29, 31, 39, 71, 145–161, 179,
 233, 234, 241, 242, 327
 recruitment fraction 146, 147
 regression coefficients 172
 regression equation 293
 regression to the mean 4, 70, 115, 119, 121
 regression towards mediocrity 119, 120
 regulatory agency 75, 77, 78, 135, 208
 relative frequencies 283
 relative risk (RR) 56, 58, 59, 72, 133, 174,
 199, 287, 288, 290–292, 299, 311, 312
 repeated assessments 318
 repeated estimates 300, 309
 replication studies 199, 202
 representativeness 240

reproducibility 36, 48, 118, 250, 294, 303
 research career development awards 328
 research qualifications 344
 research question 5, 9, 10, 16, 31, 71, 79,
 206, 249, 323–325
 residual confounding 304, 317
 resolution phase 334
 response rate 52, 102, 146–148, 150, 327
 restriction 33, 76, 77, 99, 104, 299
 retention 29, 31, 39, 40, 145–152, 233,
 241, 242
 reverse causation 295, 296
 rho-p 293
 risk difference 174, 176, 210, 288
 risk ratios 172, 173, 193, 194, 288, 304
 risk vs. benefit 157
 RNA 187
 road map 325
 rofecoxib 83, 99, 205
 Roger's diffusion theory 224
 Rosenthal's file drawer number 168
 rosiglitazone 54, 99, 206
 R-series grants 326
 r-squared 293, 294
 run-in 31, 38, 39, 121, 133, 238
 rural diabetes online care (RDOC)
 project 236, 241, 242

S

salary caps 342
 sample 6, 10, 13, 14, 19–21, 23, 25, 26,
 33–35, 37–51, 55, 56, 69, 71, 72,
 76, 81, 86, 89, 102, 103, 107, 109,
 120, 124, 131, 148, 159, 160, 163–166,
 173, 190–192, 198–202, 207, 210–212,
 214, 215, 236, 239, 240, 242, 265–281,
 285–287, 293, 299–301, 304, 307–313,
 315, 318, 319
 sample population 13, 23, 34, 37, 72, 120
 sample size calculations 239, 242, 265, 267
 sampling 10, 13, 33, 36, 37, 146, 150, 158,
 163, 165, 166, 171, 286, 301, 310, 318
 sampling distribution 266, 269, 270
 scatter plot 168
 Scurvy 5, 117
 secondary aims 266
 secular trends 209, 232
 segregation analysis 194–196
 selection bias 107, 164, 166, 170, 211, 211,
 215, 236, 237, 297, 300–302, 334
 sequence generation 236
 sham procedure 104, 106
 short tandem repeat 187, 188
 simulation models 85, 86
 single assessment 318
 single gene 185, 191, 195
 single nucleotide polymorphism (SNP) 185,
 187–191, 195–198, 201, 202
 Sir Francis Galton 119, 120
 situational analysis 223, 240
 slope of the regression line 293
 speaker-centered stage 348
 specific aims 322–327
 specific, measurable, appropriate, realistic
 and time-bound (SMART) 206
 speed demon 349
 spell-checking programs 322
 sphygmomanometer 268
 spurious relationship 303
 stage 1 348
 stage 2 348, 349
 stage 3 348
 stage-fright 345, 348
 stages of a speaker 348
 standard deviation 173, 268–270, 275–278,
 309, 310, 315
 standard error 269, 270, 273–275, 309–312
 standard error of a parameter 309
 standard error of the estimate 309
 statistical bias 299
 statistical power 36, 46, 163, 164, 238,
 265–281, 315
 statistical sample 301
 stigmatizing language 333
 stopping rules 32, 158
 stratification 30, 189, 197, 200–202, 216,
 236, 298, 299, 304, 347
 strength 4, 13, 14, 22, 23, 35, 55, 72, 77,
 78, 108, 164, 190, 206, 251, 273,
 285, 293, 310, 314, 318, 322
 strength of evidence 14
 streptomycin study 6
 STROBE 26
 stroke prevention by aggressive reduction
 in cholesterol levels (SPARCL)
 study 47
 structure of a presentation 346
 student 3, 30, 35, 36, 43, 253, 266, 286, 301,
 310, 340, 341, 346
 study population 13, 15, 146, 212, 276, 288,
 301, 304, 323
 subcohort 25
 subgroup analysis 31, 46–48, 133, 165, 314
 substantial evidence 98, 103, 119
 superiority trial 68, 158
 supplemental applications 322
 surgical interventions 83, 95, 104, 105, 108

surrogate 4, 31, 51–57, 66, 78, 86, 109, 115, 126, 131, 135, 188, 196, 197
 surveillance studies 77, 78, 81, 82, 89, 209
 survival analyses 283
 systematic error 295
 systematic error (bias) 296, 300
 systematic reviews 32, 130, 159, 163, 164, 179, 228, 230, 231, 244
 systems reengineering 230

T

talking encyclopedia 349
 target population 13, 26, 86, 146, 147, 276, 300
 telithromycin (HMR-3647) 99
 temporal 24, 206, 212
 test accuracy 253, 255, 256
 testable conjecture 270
 testable hypothesis 5, 16, 323
 TGN-1412 study 102
 thalidomide 6–8, 97, 208
 thalidomide tragedy 6, 98
 theory 19, 107, 123, 191, 224, 228, 22, 269–271, 274, 297
 titration scheme 65
 total quality management (TQM) 229
 trail duration 30, 31, 43, 57, 59, 109
 training awards 328
 transcription 187
 transdermal nitroglycerin cooperative study 126
 transmission-disequilibrium test (TDT) 199–201
 treadmill exercise testing and coronary angiography 250
 trim and fill method 168
 troglitazone 88, 205
 truth 3–5, 10, 15, 16, 18, 37, 51, 160, 179, 269, 309, 311, 312
 t-test 268, 275–278, 319

two sided test 274, 276–278, 288
 type I error 302

U

U.S. National Health and Nutrition Examination Survey (NHANES) 210
 uncertainty 13, 56, 107, 165, 266, 275, 281, 307–319
 unintended adverse events (UAEs) 66, 77, 87, 208
 universe 166, 307–309, 312
 user-friendly software packages 266
 USFDA 95, 102, 111

V

valdecixib 205
 validity 10, 38, 46, 48, 84, 85, 87, 140, 148, 149, 156, 177, 178, 238, 240, 294, 297, 299, 302, 303, 328
 variance 19, 46, 130, 165, 171, 173, 194, 239, 269, 270, 274, 283, 285, 293, 294, 319
 variation 23, 65, 82, 86, 87, 120, 171, 187–189, 194–200, 216, 235, 270, 293, 294, 299, 303, 309, 311, 318
 village of 100 37
 volunteer bias 76

W

weighted average 165, 173
 white-coat hypertension 268
 woman's health initiative 17, 71
 World Medical Association 135

Z

Z statistic 274
 Z-table 275